Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 94%
filed 2026-06-29
Item 3.02
FibroBiologics completed a private placement on June 25, 2026, raising approximately $3.0 million in gross proceeds through the issuance of 4,081,633 shares of common stock (or pre-funded warrants) and series A and B warrants exercisable for up to 8,163,266 additional shares, with potential for up to $6.0 million in additional proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions and have not been registered under the Securities Act, creating significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-29
Item 8.01
Lincoln National Corporation completed a registered public offering of $500 million aggregate principal amount of 6.800% Fixed-to-Fixed Reset Rate Subordinated Notes due 2056 on June 29, 2026. The disclosure details the underwriting agreement, terms of the notes, interest rates, redemption provisions, and use of proceeds. This is a material creation of a direct financial obligation through debt issuance, distinct from a covenant breach or other debt-related event.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-06-29
Item 8.01
The Board of Directors has authorized a distribution to stockholders across five classes of common stock (Class A, D, I, P, and T) with a record date of June 30, 2026 and payment date of approximately July 17, 2026. The distributions range from $0.0947 to $0.1042 per share net of applicable servicing fees. This is a routine but material dividend distribution to equity holders, typical for a real estate income company (REIT structure implied by the multi-class distribution approach).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-06-29
Item 8.01
The Company announced a quarterly cash dividend of $0.10 per voting and non-voting common share, payable August 7, 2026 to shareholders of record on July 17, 2026. This is a routine but material dividend declaration that affects shareholder returns and is customarily disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 8.01
DBV Technologies disclosed a regulatory milestone update regarding its BLA (Biologics License Application) submission for VIASKIN® Peanut Patch in children aged 4-7 years. The company reported productive FDA engagement, confirmation that no additional data was requested, and a revised timeline for BLA submission to Q3 2026. This is a material operational/regulatory event affecting the company's product development trajectory and investor expectations, but does not fit the specific categories of earnings release, M&A activity, impairment, or other defined event types. The disclosure centers on a strategic regulatory milestone rather than a discrete operational restructuring or contract.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-29
Item 1.01
PennantPark Private Income Fund entered into an Amended and Restated Expense Limitation and Reimbursement Agreement with its Investment Adviser on June 29, 2026. This is a material definitive agreement (Item 1.01) that restructures the financial relationship between the Company and its adviser, establishing a framework for expense support payments and reimbursement obligations. While the agreement involves a material contract between related parties, it does not constitute M&A activity, debt issuance, or other specifically-named financial event types; it is a financial arrangement governing operating expenses and adviser compensation that would affect investor assessment of the Company's cost structure and cash flows.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Blackstone Infrastructure Strategies L.P. completed unregistered private placements of limited partnership units totaling approximately $365 million across multiple unit classes (Class I, S, D, and ACC Units) to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-29
Item 1.01
Midera Food Processing entered into a $1.0 billion five-year credit agreement with Bank of America and other lenders on June 29, 2026, consisting of a $750 million U.S. dollar revolving facility and a $250 million multi-currency revolving facility. The company drew on these facilities and used cash on hand to make a $233 million distribution to Middleby Marshall Inc. in connection with its spin-off and transition to a stand-alone public company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Blackstone Private Equity Strategies Fund L.P. and its feeder fund completed unregistered sales of limited partnership units totaling approximately $992.9 million in aggregate consideration on June 1, 2026, to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-29
Item 8.01
Middleby announced the anticipated spin-off of Midera Food Processing as an independent publicly traded company, scheduled for July 6, 2026. This represents a material disposition and change of control of a significant business segment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 90%
filed 2026-06-29
Item 5.02
The Board approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) modifying their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. Concurrently, the Board adopted a Change in Control Plan and a Severance Plan establishing compensatory arrangements for eligible employees with similar benefits.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-06-29
Item 8.01
CSC issued $1,000,000,000 aggregate principal amount of 4.603% Fixed-to-Floating Rate Senior Notes due 2029, creating a new direct financial obligation. The disclosure includes the principal amount, interest rate, maturity date, net proceeds (~$995.5 million), underwriting agreement with Citigroup and Goldman Sachs, and the governing indenture documents. This is a material debt issuance under Item 2.03 (or disclosed under Item 8.01 as here), representing a significant capital-raising event for a major financial services company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
David J. Johnson, Jr. was elected as a director of Domtar Corporation by resolution of its sole shareholder on June 26, 2026. The disclosure centers on the appointment of a new director and provides his qualifications and background. While the filing also mentions a consulting agreement with Gemsbok Partners LLC, the principal disclosed action is the election of a director, making this an exec_appointment event. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
American Eagle Outfitters held its Annual Meeting of Stockholders on June 29, 2026, with stockholders voting on four proposals: election of Class I director Jay L. Schottenstein, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2023 Stock Award and Incentive Plan. All four proposals passed with reported vote tallies.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-29
Item 1.01
Scilex entered into a binding term sheet on June 24, 2026 to purchase 837 BTC from Datavault for $50 million, with an initial $30 million payment and remaining $20 million in quarterly installments through 2028, contingent on execution of a definitive agreement and satisfaction of closing conditions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-29
Item 3.02
Scilex contemplates an unregistered private placement of Company Common Stock to Datavault, an accredited investor, in a transaction exempt under Section 4(a)(2) and Regulation D Rule 506, as part of the proposed Bitcoin acquisition transaction.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-29
Item 8.01
The primary disclosure is the announcement of a preliminary proxy statement for a special shareholder meeting to vote on a share consolidation (1:5 to 1:20 ratio) intended to position TerrAscend for uplisting to a major U.S. stock exchange. While the filing also includes a segment presentation recast (New Jersey, Maryland, Pennsylvania), the salient event is the shareholder vote on the share consolidation, which is a governance matter. The consolidation is material to investors as it directly affects share structure and is a prerequisite for the company's stated uplisting strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Stockholders held on June 25, 2026. The filing presents voting results for two proposals: (1) election of Class III Directors (R. Nolan Townsend, Brenda Cooperstone, and Paula HJ Cholmondeley) and (2) ratification of KPMG LLP as the independent auditor. The tabulated vote counts (FOR, WITHHELD/AGAINST, BROKER NON-VOTE/ABSTAIN) are the hallmark of shareholder vote result disclosures.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-29
Item 1.01
Andersen Group Inc. entered into a $50 million asset-based revolving credit facility with JPMorgan Chase Bank on June 25, 2026. This is a material creation of a new direct financial obligation—a credit agreement establishing a revolving credit facility with specified terms, interest rates (Term SOFR + 175 bps), covenants, and collateral requirements. The facility is secured by first lien on all assets of the Loan Parties and includes guarantees from multiple subsidiaries, making it a significant financing event material to investors.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-06-29
EX-99.1
This is a press release announcing topline results from ABTECT Maintenance Part 2, a Phase 3 clinical trial of obefazimod for ulcerative colitis. The disclosure reports efficacy and safety data from a material clinical milestone—specifically, positive results in a refractory patient population and expanded safety database—that would affect a reasonable investor's assessment of the company's lead drug candidate and regulatory pathway. The company explicitly states it remains "on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026," making these trial results directly relevant to near-term value drivers. While this is not a financial earnings release in the traditional sense, it is a material clinical results announcement that functions as a discrete event disclosure of significant business importance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-29
Item 5.02
Karen Grimes, Marcos Lutz, Charles Magro, and Kerry Preete resigned from Corteva's board of directors effective immediately prior to the spin-off consummation, representing a significant change in board composition for the parent company in connection with the planned separation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-29
Item 7.01
Corteva announced the post-separation boards of directors for Corteva and Vylor in connection with its planned separation of its seed business into an independent public company, scheduled for 4Q 2026, constituting a material disposition of a business segment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-29
Item 3.02
Digital Realty entered into an agreement to acquire Blackstone's 64% equity interests in two Northern Virginia data center joint ventures (Digital Carver Dulles 9 and Digital Carver Brickyard) for $3.5 billion in total consideration ($1.231 billion cash and $2.346 billion in non-voting common stock), resulting in wholly owned subsidiaries controlling 288 megawatts across three hyperscale facilities valued at $7.8 billion gross.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-29
Item 1.01
Contango Silver & Gold entered into a First Amendment to the Membership Interest Purchase and Sale Agreement on June 26, 2026, settling $18.75 million in milestone payment obligations for $5 million cash and 100,000 common shares. This amendment eliminates remaining contingent liabilities and encumbrances on the Lucky Shot Project, securing 100% unencumbered control of the asset and materially modifying the Company's ownership and financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
The filing discloses an unregistered sale of 560,488.164 shares of Class I common stock for approximately $8.0 million, exempt under Section 4(a)(2) of the Securities Act and Regulation D. This is a classic dilutive equity issuance by a BDC raising capital through a private placement, which materially affects existing shareholders' ownership percentages and is a significant capital event for the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-29
Item 5.07
IMMUNIC held its annual stockholder meeting and disclosed final voting results, including election of three Class III Directors (Michael Bonney, Thorvald Nagel, and Richard Rudick), approval of an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000, and ratification of Baker Tilly as independent auditor.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 8.01
Star Equity Holdings announced its inclusion in the Russell Microcap Index following the 2026 reconstitution, effective June 26, 2026. While this is a positive operational/strategic milestone that increases institutional visibility and investor awareness, it does not fit neatly into any specific event category. The company characterizes it as "a meaningful milestone" that "expands our visibility within the institutional investment community." This is a material operational event reflecting market recognition and improved access to capital markets, but it is not a governance matter, financial obligation, M&A activity, or other named event type.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-29
The filing discloses that T1 Energy's publicly traded warrants will expire on July 9, 2026, cease trading on the NYSE under symbol "TE WS" before market open that day, and the NYSE intends to file a Form 25 with the SEC to effect delisting and deregistration of the Public Warrants under Section 12(b) of the Securities Exchange Act. This is a material delisting event affecting the warrant securities, though the Common Stock will continue trading under "TE."
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
The Company issued 1,310,969 shares of common stock to ASPIS Cyber Technologies for $1.7 million under a Stock Purchase Agreement dated April 15, 2026, consummated on June 26, 2026. The issuance is explicitly exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, which are hallmarks of a private placement. This unregistered equity issuance is material to investors as it represents significant dilution and capital raising activity.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-06-29
The 6-K discloses the Second Closing on June 25, 2026, whereby Kandal M Venture Limited issued a $1,000,000 senior unsecured convertible promissory note bearing 10% interest, maturing June 5, 2029, and convertible into Class A Ordinary Shares. This is a material creation of a direct financial obligation under a securities purchase agreement with an institutional investor, fitting the debt_issuance category. The convertible feature and registration rights agreement are ancillary to the core debt issuance event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
EX-99.1
This press release announces the closing of a registered direct offering of 400,000 ADSs at $10.00 per ADS (a 10.7% premium to market) plus warrants to purchase 300,000 additional ADSs, raising $4.0 million gross proceeds. The offering was made pursuant to an effective Form F-3 shelf registration statement, making it a registered equity issuance. While registered offerings are technically not "unregistered" in the strict sense, this is a dilutive equity issuance that materially increases share count and is the type of capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-29
Item 1.01
PVH Corp. entered into a new Credit Agreement on June 24, 2026, creating direct financial obligations consisting of a €400 million euro-denominated term loan facility and a US$1.5 billion multicurrency revolving credit facility. The company used proceeds from the new borrowing to repay and terminate its prior credit agreement dated December 9, 2022. This is a material refinancing and debt issuance event that creates new direct financial obligations under Item 2.03.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
Bitdeer announced execution of a colocation lease agreement for its Tydal, Norway AI data center site through its subsidiary Tydal Data Center AS. This is a material operational/strategic event involving infrastructure expansion for the company's core AI and Bitcoin mining business. While the lease has not yet become effective and remains subject to conditions precedent, the signing of a major data center colocation agreement represents a significant step in the company's global infrastructure strategy and would affect a reasonable investor's assessment of the company's operational capacity and growth trajectory. The event does not fit neatly into predefined categories like `ma_activity` (not an acquisition or merger) or `debt_issuance` (not a financial obligation), making `operational_other` the most appropriate classification for this material strategic infrastructure commitment.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-06-29
EX-99.1
The press release announces the status and progress of a shareholder-approved business combination between Check-Cap Ltd. and MBody AI Corp., which is described as "on track to close in the second half of 2026, subject to customary closing conditions." The disclosure includes material updates on the merger's advancement, including Nasdaq's completion of its initial listing review and the companies' responses to supplemental information requests. While the merger itself was previously disclosed, this exhibit reports a material update on the transaction's progress toward completion, which is a form of M&A activity disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-29
Item 1.01
SandRidge Energy entered into a definitive Purchase and Sale Agreement on June 26, 2026, to acquire oil and gas properties and related assets in the Cherokee Play for $65 million in cash plus up to $6 million in contingent earn-out payments. The acquisition includes approximately 3.0 MBoed production, 7,000 net leasehold acres, and 21 wells, and is characterized as immediately accretive to production, EBITDA, and free cash flow.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-06-29
EX-99.1
This is a press release announcing positive Phase 2b clinical trial results for NeuroSense's lead drug candidate PrimeC in ALS. The disclosure reports achievement of the primary efficacy endpoint (statistically significant TDP-43 reduction, p=0.0421), previously reported clinical outcomes including slowing of disease progression and survival benefit, and advancement toward Phase 3 trials. While not a financial earnings release in the traditional sense, this is a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and prospects. The language ("achieved primary endpoint," "statistically significant," "compelling body of evidence") and the detailed clinical data presentation mirror the structure and materiality of an earnings-type announcement for a clinical-stage biotech company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
This press release announces Park Ha Biological's strategic partnership with Amazon to enter the North American personal care market, including store qualification, brand registry enrollment, and compliance framework establishment. This is a material operational and strategic business event—a significant market-expansion initiative that would affect a reasonable investor's assessment of the company's growth prospects and international strategy. While it does not fit the specific categories of M&A activity, debt issuance, or workforce reduction, it clearly represents a major operational milestone and strategic partnership that warrants disclosure as a material event.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-06-29
EX-99.1
The exhibit is a shareholder letter dated June 29, 2026, following the Company's Annual General Meeting on June 26, 2026. It explicitly references the AGM vote ("Your vote is not something we take for granted") and reports the Board's mandate and plans to expand independent director representation. While the letter also contains forward-looking strategic commentary, the core disclosure is the AGM outcome and the Board's response, which constitutes shareholder vote results under Item 5.07 equivalent for a foreign private issuer.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-06-29
Mr. Philip Ling Yan Wong resigned from the Board of Directors and as Co-CEO of Concorde International Group Ltd. effective June 28, 2026. The departure of a Co-CEO and board member is a material executive departure that would affect a reasonable investor's assessment of the company's leadership and governance. The filing explicitly discloses this as a "Departure of Directors or Certain Officers."
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-29
Item 4.01
The filing discloses the simultaneous dismissal of BCRG as the Company's independent registered public accounting firm and appointment of Simon & Edward LLP as the new auditor, effective June 23, 2026. This is a classic auditor change under Item 4.01. While the disclosure also mentions BCRG's going-concern qualification in prior audit reports, the principal event disclosed is the change in auditors itself, not the going-concern matter (which was previously disclosed). The materiality is high given the change in the registrant's certifying accountant.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-29
This 8-K discloses a Shareholder Q&A document issued following the June 10, 2026 annual meeting. The filing references Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits), and the Q&A addresses shareholder-approved governance matters including a corporate name change from Triller Group Inc. to Eight Holdings Inc., authorization for a reverse stock split (which was effected on June 25, 2026 at 1-for-10), adoption of a 2026 Equity Incentive Plan, and Nasdaq 20% issuance approval for private placements. While the document contains strategic and operational commentary, the core disclosure event is governance-related—shareholder meeting outcomes and corporate identity/structure changes. The reverse split and name change are material governance actions affecting the registrant's public-company status and shareholder rights.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-29
EX-99.1
The press release announces Kandi Technologies' entry into an investment agreement to acquire a 51% controlling stake in Hangzhou Xinchu New Energy Technology Co., Ltd. for RMB20 million (approximately US$2.9 million), with expected close in July 2026. This constitutes a material acquisition and change of control event under Item 1.01 of Form 8-K (or equivalent 6-K disclosure), establishing Kandi's strategic expansion into the AI data center backup power and energy storage market.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-29
The 6-K discloses a proposed private placement of 14,000,000 new ordinary shares at KRW 1,600 per share (total KRW 22.4 billion / HKD 113.6 million) to three subscribers including two individuals and a related entity. This is a dilutive equity issuance requiring shareholder approval at the August 10, 2026 EGM, with proceeds earmarked for working capital (procurement, marketing, R&D). The transaction materially dilutes existing shareholders and raises capital through unregistered equity sales.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-29
EX-99.1
The Company received a Nasdaq notification letter on June 26, 2026, stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) because the closing bid price was below $1.00 per share for 30 consecutive business days. The Company has 180 calendar days until December 23, 2026, to regain compliance, or it may face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
Polyrizon announced receipt of central IRB approval from BRANY to begin its first human clinical trial for NASARIX™, an intranasal hydrogel allergy blocker. This is a material regulatory milestone for a development-stage biotech company—it represents significant progress toward commercialization of a lead product candidate and enables advancement to site activation and patient enrollment. While not fitting a discrete named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development trajectory and near-term prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-29
Item 1.01
Alpex Acquisition Corp entered into multiple material definitive agreements in connection with its IPO and concurrent private placement, including the Underwriting Agreement, Warrant Agreement, Rights Agreement, and Investment Management Trust Agreement, representing a material capital-raising transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Alpex completed an unregistered private placement of 187,500 Private Units to the Sponsor for $1,875,000 substantially concurrent with the IPO closing, with units subject to transfer restrictions until completion of the initial business combination.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Three independent directors—Yi Hua, Xin Yue Jasmine Geffner, and Yuanmei Ma—were appointed effective June 25, 2026, in connection with the Company's Nasdaq listing and IPO closing, with Geffner designated as audit committee chair and qualified audit committee financial expert.
View raw filing on EDGAR →
8-K
Financial Other
confidence 65%
filed 2026-06-29
Item 8.01
Alpex Acquisition Corp completed its initial public offering of 11.5 million units raising $115 million in gross proceeds, with concurrent private placement of 187,500 units, representing a material capital-raising transaction for the newly public blank-check SPAC.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-29
The Company issued 500,000 warrants to purchase ordinary shares at $6.25 per share to Taurus Mining Finance on June 29, 2026, pursuant to a waiver letter related to a $60 million senior secured bridge loan facility. This is a dilutive equity issuance tied to debt financing and represents a material capital structure event affecting existing shareholders.
View raw filing on EDGAR →